section name header

Pronunciation

se-LE-ji-leen

Classifications

Therapeutic Classification: antiparkinson agents, antidepressants

Pharmacologic Classification: monoamine oxidase type b inhibitors

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed following oral administration. 25–30% of patch content is absorbed; levels are higher than those following oral administration because there is less first-pass hepatic metabolism.

Distribution: Widely distributed to tissues; crosses the blood-brain barrier.

Metabolism/Excretion: Mostly metabolized by the liver, primarily by the CYP2A6, CYP2C9, and CYP3A4/5 isoenzymes to N-desmethylselegiline, amphetamine, and methamphetamine as well as inactive metabolites. Primarily excreted in urine as metabolites.

Half-life: Oral: 10 hr; Transdermal: 20 hr.

Time/Action Profile

(beneficial effects in Parkinson’s disease)

ROUTEONSETPEAKDURATION
PO2–3 days40–90 minunknown
Orally disintegrating5 min10–15 minunknown
Transdermalunknownge.gif2 wkunknown

† Beneficial effects in Parkinson’s disease; dhara Antidepressant effects

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: orthostatic hypotension.

Derm: Transdermal: application site reactions, acne, ecchymoses, pruritus, sweating.

GI: nausea, abdominal pain, diarrhea, dry mouth.

Neuro: aggression, agitation, confusion, delirium, delusions, disorientation, dizziness, fainting, hallucinations, headache, insomnia, paranoia, psychosis, sedation, SEROTONIN SYNDROME, urges (gambling, sexual), vivid dreams.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Route/Dosage

Parkinson's Disease

Depression

Availability

(Generic available)

Assessment

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Eldepryl, Emsam, Zelapar